Microchip Technology Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Microchip Technology Inc. trades at $79.48 (market cap $43.99B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Microchip Technology Inc. is far larger — about 2.4× Zimmer Biomet Holdings Inc's market cap, and Microchip Technology Inc. pays the higher dividend (2.25%). Which is the better fit depends on your goals.
| MCHP | ZBH | |
|---|---|---|
Market Cap | $43.99B | $18.55B |
Sector | Technology | Health |
52-Week High | $102.97 | $107.71 |
52-Week Low | $49.02 | $79.58 |
Enterprise Value | $49.12B | $25.61B |
Dividend Yield | 2.25% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $80.11, down 1.57% over the past day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and robust data center revenue growth, including a 98% surge last quarter, highlight operational momentum. The company maintains solid cash flow and a healthy balance sheet, though elevated valuation ratios like a P/E of 119.15 warrant caution.
Outlook remains positive driven by AI and data center demand, with a consensus price target of $104 implying significant upside. Risks include high debt levels and sensitivity to semiconductor cycles. Institutional sentiment is strong with no sell ratings among 44 analysts, supporting a favorable investment case amid broader tech recovery trends.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →